Poseida Therapeutics Inc

NASDAQ:PSTX   3:59:53 PM EDT
6.49
+0.16 (+2.53%)
Products, Strategic Combinations

Poseida Therapeutics Announces Research Collaboration With Takeda For Novel Non-Viral In Vivo Gene Therapies

Published: 10/12/2021 11:23 GMT
Poseida Therapeutics Inc (PSTX) - Poseida Therapeutics Announces Research Collaboration With Takeda for Novel Non-viral in Vivo Gene Therapies.
Poseida Therapeutics - Parties to Collaborate to Initially Develop Up to Six in Vivo Gene Therapy Programs Utilizing Co's Novel Technology Platforms.
Poseida Therapeutics Inc - Takeda Also Has an Option to Add Two Additional Programs to Collaboration.
Poseida Therapeutics Inc - Takeda is Obligated to Provide Funding for All Collaboration Program Research and Development Costs.
Poseida Therapeutics Inc - Will Receive an Upfront Payment of $45 Million.
Poseida Therapeutics - Will Receive Preclinical Milestones That Together Could Potentially Exceed $125 Million, If Milestones for 6 Programs Are Achieved.
Poseida - Eligible to Get Future Milestone Payments With Potential Value of Up to $2.7 Billion If Milestones for 6 Programs Are Achieved.
Poseida Therapeutics Inc - Eligible to Receive Up to $3.6 Billion If Milestones Related to Two Optional Programs Are Also Achieved.